Crigler-Najjar Syndrome - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--()--The "Crigler-Najjar Syndrome - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Crigler-Najjar Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Key Topics Covered:

  1. Crigler-Najjar Syndrome - Overview
  2. Crigler-Najjar Syndrome - Therapeutics Development
  3. Pipeline Overview
  4. Pipeline by Companies
  5. Pipeline by Universities/Institutes
  6. Products under Development by Companies
  7. Products under Development by Universities/Institutes
  8. Crigler-Najjar Syndrome - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Crigler-Najjar Syndrome - Companies Involved in Therapeutics Development
  • Audentes Therapeutics Inc
  • Genethon SA
  • International Stem Cell Corp
  • Promethera Biosciences SA

For more information about this report visit https://www.researchandmarkets.com/research/zn65ng/criglernajjar

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Endocrine and Metabolic Disorders Drugs